These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32935744)

  • 1. MELD EXCEPTION POINTS PROVIDE AN ENOURMOUS ADVANTAGE FOR RECEIVING A LIVER TRANSPLANT IN BRAZIL.
    Arruda S; Chedid MF; Jacinto MM; Álvares-DA-Silva MR
    Arq Gastroenterol; 2020; 57(3):254-261. PubMed ID: 32935744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
    Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
    J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
    J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
    Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
    Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the organ allocation system for liver transplantation in Chile].
    Wolff R; Díaz LA; Norero B; Urzúa Á; Mezzano G; Humeres R; Innocenti F; Castro L; Pavez C; Derosas C; Elgueta S
    Rev Med Chil; 2020 Nov; 148(11):1541-1549. PubMed ID: 33844759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
    Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
    Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change.
    Saberi B; Gurakar A; Tamim H; Schneider CV; Sims OT; Bonder A; Fricker Z; Alqahtani SA
    JAMA Netw Open; 2023 Nov; 6(11):e2341096. PubMed ID: 37917059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of MELD score implementation on liver allocation: experience at a Brazilian center.
    da Silva Machado AG; de Medeiros Fleck A; Marroni C; Zanotelli ML; Cantisani G; de Mello Brandão AB
    Ann Hepatol; 2013; 12(3):440-7. PubMed ID: 23619261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waitlist mortality and post-liver transplant outcomes of pediatric patients with hepatocellular carcinoma and hepatoblastoma in the United States.
    Wu WK; Ziogas IA; Matsuoka LK; Izzy M; Pai AK; Benedetti DJ; Alexopoulos SP
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29425. PubMed ID: 34736292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator.
    Díaz LA; Norero B; Lara B; Robles C; Elgueta S; Humeres R; Poniachik J; Silva G; Wolff R; Innocenti F; Rojas JL; Zapata R; Hunter B; Álvarez S; Cancino A; Ibarra J; Rius M; González S; Calabrán L; Pérez RM
    Ann Hepatol; 2019; 18(2):325-330. PubMed ID: 31010794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.
    Jurado-García J; Muñoz García-Borruel M; Rodríguez-Perálvarez ML; Ruíz-Cuesta P; Poyato-González A; Barrera-Baena P; Fraga-Rivas E; Costán-Rodero G; Briceño-Delgado J; Montero-Álvarez JL; de la Mata-García M
    PLoS One; 2016; 11(6):e0155822. PubMed ID: 27299728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.